Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor(TM) in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients

GlobeNewswire September 1, 2020

European Patent Granted Covering INmune Bio's XPro1595

GlobeNewswire August 13, 2020

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update

GlobeNewswire August 5, 2020

INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020

GlobeNewswire August 3, 2020

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

GlobeNewswire July 31, 2020

INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm

GlobeNewswire July 27, 2020

Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option

GlobeNewswire July 20, 2020

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option

GlobeNewswire July 20, 2020

INmune Bio, Inc. Prices Public Offering of Common Stock

GlobeNewswire July 16, 2020

INmune Bio, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire July 15, 2020

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer's Disease

GlobeNewswire July 13, 2020

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer's Disease Prior to Start of AAIC 2020

GlobeNewswire July 9, 2020

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS

GlobeNewswire June 11, 2020

Killers at the Crossroad - A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc.

GlobeNewswire May 19, 2020

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

GlobeNewswire May 14, 2020

INmune Bio Inc's INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer

GlobeNewswire May 11, 2020

INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call

GlobeNewswire May 6, 2020

INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group's Infectious Disease Virtual Conference on May 5, 2020

GlobeNewswire April 28, 2020

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF's Impact on Breast Cancer

GlobeNewswire April 23, 2020

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells

GlobeNewswire April 22, 2020